Fluoroquinolone antibacterial agent. Structurally similar to ofloxacin. Specific inhibitor of bacterial DNA gyrase (topoisomerase). Inhibits B-cell differentiation. Shows photosensitizing effects.
Product Details
Alternative Name: | 6-Fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid . hydrochloride, MF-934 . hydrochloride |
|
Formula: | C17H18FN3O3S . HCl |
|
MW: | 363.4 . 36.5 |
|
CAS: | 106017-08-7 |
|
MI: | 14: 8294 |
|
Purity: | ≥98% (Assay) |
|
Identity: | Identity determined by IR. |
|
Appearance: | Off-white to light green crystalline solid. |
|
Solubility: | Sparingly soluble in water; very slightly soluble in methanol; almost insoluble in chloroform or acetic acid. |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Rufloxacin-induced photosensitization in yeast: A. Catalfo, et al.; Photochem. Photobiol. Sci.
6, 181 (2007),
Abstract;
Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges: M.V. Moretti, et al.; Antimicrob. Agents Chemother.
44, 73 (2000),
Abstract;
Full Text
Molecular mechanisms of photosensitization induced by drugs. XII. Photochemistry and photosensitization of rufloxacin: an unusual photodegradation path for the antibacterials containing a fluoroquinolone-like chromophore: G. Condorelli, et al.; Photochem. Photobiol.
70, 280 (1999),
Abstract;
Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria: L.J. Piddock, et al.; J. Antimicrob. Chemother.
31, 855 (1993),
Abstract;
Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis: W. Klietmann, et al.; Antimicrob. Agents Chemother.
37, 2298 (1993),
Abstract;
Full Text
Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group: R. Mattina, et al.; Infection
21, 106 (1993),
Abstract;
Effect of rufloxacin on in-vitro proliferation and differentiation of human mononuclear cells: S. Gollapudi, et al.; J. Antimicrob. Chemother.
29, 669 (1992),
Abstract;
Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers: J.C. Kisicki, et al.; Antimicrob. Agents Chemother.
36, 1296 (1992),
Abstract;
Full Text
The in-vitro activity of two new quinolones: rufloxacin and MF 961: R. Wise, et al.; J. Antimicrob. Chemother.
29, 649 (1992),
Abstract;
Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids: V. Cecchetti, et al.; J. Med. Chem.
30, 465 (1987),
Abstract;